Compounds / Cerebrolysin

Cerebrolysin

Porcine brain peptide preparation

Cerebrolysin has 37 registered human trials — it is genuinely well studied. The question worth asking is what those trials were studying, because it is often not what the compound is sold for.

In short

  • 37 registered human trials exist for Cerebrolysin.
  • No registered trial lists neuroprotection or anti-aging as a studied condition.
  • Cerebrolysin is not FDA-approved for any use.
  • What has actually been studied: disorder of consciousness, hemorrhagic stroke.
  • 7 studies are open to new participants, so this may change.
  • Last checked against ClinicalTrials.gov on 2026-07-27.
37
Registered human trials
9
Under way, incl. closed to enrolment
No
FDA approved
Pre
P1
P2
P3
Furthest stage reached

Not FDA-approved for any indication. Approved in Russia, China, Austria and other countries for stroke and dementia — a different regulatory system with different evidence standards.

What it's sold for

  • Cognitive enhancement
  • Brain recovery
  • Neuroprotection
  • Anti-aging

What has actually been tested

  • Stroke
  • Acute Ischemic Stroke
  • Alzheimer Disease
  • Cerebrolysin
  • Hemorrhagic Stroke
  • Ischemic Stroke
  • Ischemic Stroke, Acute
  • Traumatic Brain Injury

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Studied Cognitive enhancement
Studied Brain recovery
Not listed Neuroprotection
Not listed Anti-aging

Every trial on record

Every registered human study we can find for Cerebrolysin. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial IDTitleConditionPhaseStatusEnrolled
NCT04427241 Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness Disorder of Consciousness, Hemorrhagic Stroke Phase 4 Recruiting now 12
NCT06489925 Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion Basilar Artery Occlusion, Posterior Circulation Brain Infarction Phase 1 Not yet recruiting 20
NCT06899464 Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral Phase 4 Not yet recruiting 30
NCT06897176 Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study Stroke Phase 4 Recruiting now 40
NCT06339411 Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights Acute Ischemic Stroke Phase 1 Not yet recruiting 100
NCT07043686 Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study Ischemic Stroke, Acute, Rehabilitation Outcome Not phased Recruiting now 30
NCT05821075 Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy Bell Palsy Phase 2 Recruiting now 90
NCT02149875 Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke Acute Cerebral Stroke Within 12 Hours for the First Time Phase 2 Completed 84
NCT03506841 Cerebrolysin and Neurodevelopment in Preterm Infants Infant Development, Cerebral Palsy Phase 1 Completed 60
NCT01388738 Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. Stroke Phase 3 Completed 30
NCT01059461 Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy Hypoxic-Ischemic Encephalopathy Phase 2 Completed 40
NCT01787123 Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage Subarachnoid Hemorrhage, Intracranial Aneurysm Phase 3 Completed 50
NCT04751136 the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome Down Syndrome Phase 2 Completed 64
NCT00868283 The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke Ischemic Stroke Phase 4 Completed 1071
NCT06208540 Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants Post-covid-19 Persistent Smell and Taste Disorders Phase 4 Completed 160
NCT02768571 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Stroke Phase 4 Completed 80
NCT05288465 Hair Repigmentation During Cerebrolysin Therapy Hair Problems Not phased Completed 5
NCT00840671 Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke Stroke Phase 3 Completed 119
NCT01996761 Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke Cerebrolysin Phase 4 Completed 71
NCT00947531 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Vascular Dementia Phase 4 Completed 242
NCT06052787 Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU Traumatic Brain Injury Phase 3 Completed 150
NCT00911807 Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease Alzheimer Disease Phase 2 Completed 217
NCT04830943 Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia Covid19 Related Anosmia and Aguesia Phase 3 Completed 250
NCT04913831 Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study Stroke Phase 4 Status not updated 30
NCT06677502 Cerebrolysin in Critically Ill Patients With Delirium Cognitive Impairment Not phased ENROLLING_BY_INVITATION 500
NCT04904341 Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke. Stroke, Ischemic, Stroke, Acute Phase 3 Status not updated 50
NCT06078215 CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke Acute Ischemic Stroke Phase 4 Status not updated 350
NCT02581371 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Ischemic Stroke Phase 4 Status not updated 30
NCT05864677 Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery Neurocognitive Disorders, Surgery-Complications Not phased Status not updated 100
NCT02116348 Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy Cerebral Palsy Children, Children With Traumatic Brain Injury Phase 2 Status not updated 100
NCT06273020 Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke Ischemic Stroke, Acute, Diabetes Mellitus, Type 2 Phase 4 Status not updated 60
NCT05124353 Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT Stroke, Acute, Ischemic Phase 3 Status not updated 100
NCT05755997 CERebrolysin In CADASIL Cadasil Phase 2 Running, closed to new participants 30
NCT01606111 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Traumatic Brain Injury Phase 4 Stopped early 46
NCT01822951 Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) Alzheimer Disease Phase 4 Withdrawn before enrolling 0 — nobody enrolled
NCT04124367 IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE Chronic Stroke, Subacute Stroke Phase 2 Stopped early 4
NCT06070753 A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT) Acute Ischemic Stroke Not phased Status not updated 30
—Read this
A trial count is not a verdict
These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Why sources disagree on this number

Different sites publish different counts for Cerebrolysin because they are answering different questions. Here is every way of counting the same set of studies, so you can see which rule produces which number.

37
Registered human trials the number we publish
Interventional studies in people, listed on ClinicalTrials.gov, at any status.
16
Completed
Registered trials whose status is "completed".
9
Still running
Recruiting, not yet recruiting, or active.
3
Stopped early
Terminated, withdrawn, or suspended.
32
With a stated phase
Registered trials tagged Phase 1-4.
13
100+ participants
Registered trials enrolling at least 100 people.
5
Observational studies
Studies that watch rather than intervene.
You may see a lower number than 37.

Sources that count only completed studies get 16. We count registered trials at any status, because a trial that is recruiting is still a real trial and is the thing most likely to change this page. Neither number is wrong; they answer different questions.

Some counts only include trials with a stated phase.

That yields 32 rather than 37. Not every registered study is tagged with a phase — some are marked "not applicable" — so phase-only counts run lower.

Which number should you use?

For "how much human evidence exists", 37 is the honest answer, with the caveat that 16 have actually finished. Every trial is listed on this page with its ID — if you disagree with how we count, you can recount it yourself in about a minute.

Common questions about Cerebrolysin

How many human trials does Cerebrolysin have?

37. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Cerebrolysin FDA approved?

No. Cerebrolysin is not approved by the FDA for any indication. Compounded or "research use only" preparations are not FDA-approved and receive no premarket review for safety, effectiveness, or manufacturing quality.

What is Cerebrolysin actually being tested for?

Registered studies cover: disorder of consciousness, hemorrhagic stroke, basilar artery occlusion. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.

Get told when this changes

One email a week: what moved in the research, and which claims the record doesn't support. Free, and you can leave in one click.